



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

Patient Organisation Agreement

This Patient Organisation Agreement has been drawn up and entered into as of 19 August 2022 by and between

CSL Behring AB, Box 712, 182 17 Danderyd, SWEDEN, Reg. no. 556530-1974

and

Alpha 1 Denmark Sangfuglestien 5, st. 2400 København NV info@alfa-1.dk

1. Background

Alpha-1-antitrypsin deficiency (ZZ) can cause lung disease, rarer liver disease in adults and in some children also liver disease from birth.

The purpose of the alfa-1 Denmark is to optimize living conditions for people with Alpha-1 antitrypsin deficiency and create a forum for Alfa-1 patients and their relatives for mutual support, exchange of experience and knowledge acquisition. The aim is also to gain public understanding, acceptance and support to meet the needs of Alpha-1 patients and promote international cooperation on Alpha-1 antitrypsin deficiency.

CSL Behring operates in this field by improving treatment for patients living with alpha-1-antitrypsin deficiency (ZZ).

There is a common interest in improving alpha-1-antitrypsin treatment and care and to drive advocacy for improved patient access to treatment and care in Denmark but also to support the other Nordic countries.

2. Collaboration project

To support Alpha-1 patients in the Nordic countries CSL Behring support a Nordic meeting arranged in Oslo with lead from Alpha-1 Denmark.

The support will be given as an unrestricted grant. Alpha-1 Denmark estimates the total cost 14 523 DKK (See attachment 1).

3. Finances

3.1 CSL Behring AB has undertaken to finance the project Nordisk møde with 14 523 DKK. Payment shall be made against separate invoice. The invoice shall be sent to DanderydPayables@cslbehring.com

State Therese Feinberg as reference on the invoice.

4. Transparency

4.1 Both Parties consent to the contents of this Agreement being shared with a third party.

4.2 Both parties consent to this agreement or a summary thereof being published on the company website and reported to ENLI in accordance with § 3 of the Patient Organizations Code regulated by the Ethical Committee for the Pharmaceutical Industry, ENLI.

5. Consultation, evaluation

5.1 Alpha 1 Denmark has appointed Formand Claus Astradsson and Heinrich Andreasen as their contact persons in matters concerning this Agreement.



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

5.2 CSL Behring AB has appointed Therese Feinberg as their contact person in matters concerning this Agreement.

6. Agreement period and early termination

6.1 This Agreement is valid from 19/08/2022 until 31/08/2022.

6.2 If either party fails to fulfil their obligations pursuant to this Agreement and adjustments have not been made within thirty (30) days of the party being requested in writing to do so, the other party will be entitled to terminate the Agreement immediately.

7. Ethical rules and law

7.1 Ethical rules and national law apply to this agreement. Alpha 1 Denmark warrants that it will only use the funds received in accordance with national law and the Pharmaceutical Industry's Code of Ethics.

7.2 Alpha 1 Denmark may not refer to or make any representation relating to CSL Behring or its products or the co-operation under this agreement without CSL Behring's prior written approval. Alpha 1 Denmark shall submit all proposed materials mentioning CSL Behring, or referring to CSL Behring's products, or the co-operation under this agreement, to CSL Behring for written approval prior to publication or use.

8. Disputes

If a dispute should arise in conjunction with this Agreement, the Parties shall primarily attempt to resolve it through negotiation. In the event that the Parties are unable to reach an accord within thirty (30) days of the initial request for negotiation, the dispute shall be resolved in a Swedish Court.

9. E-signature

The Agreement may be executed by means of wet ink signatures or by using electronic signatures. If the Agreement is signed using electronic signatures, in making proof of this Agreement, an electronic copy of the Agreement will suffice. The Parties undertake not to dispute the validity of the Agreement based on the signatures being electronic.



Berga Backe 2, Box 712, 182 17 Danderyd, Sweden

This Agreement has been drawn up and signed in two (2) identical originals, of which each party has received an original.

Place and Date: Danderyd 220819

CSL Behring AB:

DocuSigned by:

Petter Olbe

.....181413637D10475.....

Name and title:

Petter Olbe

Marketing Manager, Nordic Region

Place and Date: 19-08-2022

Alpha 1 Denmark:

DocuSigned by:

Claus Astradsson

.....49F4EE1#4E1E#6E.....

Name and title:

Claus Astradsson

Formand

Place and Date: Västra Hagen 220819

CSL Behring AB:

DocuSigned by:

Martin Tenlen

.....3BBB2BD230484A1.....

Name and title:

Martin Tenlen

General Manager, Nordic Region

Attachment 1:

					
Ansøgning.					
<p>Alfa-1 Danmark ansøgning vedrørende deltagelse / afholdelse af Nordisk møde i København, mødet afholdes fra d.12-13/ Foremål med mødet er at øge det nordiske samarbejde, så kendskabet til brug af medecin kan blive udbredt i de andre nordiske lande. Der er allerede nu planlagt møde igen fredag d. 2/9 i københavn, hvor vi vil igangsætte arbejde med etablering af en nordisk Alfa-1 Forening</p>					
Budget for Nordisk møde til afholdelse i August 2022					
Diverse udgifter.	Omkostninger				
Flybilletter 2 stk retur København-Norge (2 x 1655,-)	kr. 3 330,00				
Hotelværelser 2 stk Overnatning fredag-søndag	kr. 6 325,00				
Leje af møde lokale fredag-lørdag (gratis lånt lokale på Oslo Bibliotek)	kr. 0,00				
Parkering københavn 388,- transport til og fra oslo 2x440	kr. 1 268,00				
Transport Gunhil Fyn København	kr. 600,00				
forplejning fredag-lørdag	kr. 3 000,00				
	kr. 0,00				
	kr. 14 523,00				